We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A new study has assessed the safety, tolerability, and effectiveness of extended-release guanfacine in children 6-17 years of age who have chronic tic disorders including Tourette’s disorder.